INTRATUMORAL ADAPTIVE IMMUNOSUPPRESSION AND TYPE 17 IMMUNITY IN MISMATCH REPAIR PROFICIENT COLORECTAL TUMORS

PURPOSE: Approximately 10% of mismatch repair proficient (MMRp) colorectal cancer (CRC) patients showed clinical benefit to anti-PD-1 monotherapy (). We sought to identify biomarkers that delineate patients with immunoreactive CRC and to explore new combinatorial immunotherapy strategies that can im...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Llosa, Nicolas J., Luber, Brandon, Tam, Ada J., Smith, Kellie N., Siegel, Nicholas, Awan, Anas H., Fan, Hongni, Oke, Teniola, Zhang, JiaJia, Domingue, Jada, Engle, Elizabeth L., Roberts, Charles A., Bartlett, Bjarne R., Aulakh, Laveet K., Thompson, Elizabeth D., Taube, Janis M., Durham, Jennifer N., Sears, Cynthia L, Le, Dung T, Diaz, Luis A., Pardoll, Drew M., Wang, Hao, Anders, Robert A., Housseau, Franck
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726531/
https://ncbi.nlm.nih.gov/pubmed/31061070
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0114
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars